Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have received an average recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $56.33.

Several brokerages recently weighed in on AGIO. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Leerink Partnrs lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Scotiabank increased their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday. Finally, Raymond James restated an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, October 10th.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now owns 20,158 shares of the company’s stock, valued at $988,346.74. This represents a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several large investors have recently made changes to their positions in the stock. Caxton Associates LP increased its position in shares of Agios Pharmaceuticals by 0.7% during the second quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock worth $1,615,000 after acquiring an additional 264 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Agios Pharmaceuticals by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 363 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Agios Pharmaceuticals by 6.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company’s stock worth $539,000 after acquiring an additional 688 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the second quarter worth $37,000. Finally, Quest Partners LLC bought a new stake in shares of Agios Pharmaceuticals during the second quarter worth $40,000.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO opened at $46.02 on Wednesday. The company’s 50 day simple moving average is $50.09 and its 200 day simple moving average is $46.68. Agios Pharmaceuticals has a fifty-two week low of $20.96 and a fifty-two week high of $62.58. The firm has a market capitalization of $2.62 billion, a P/E ratio of 4.05 and a beta of 0.80.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.